Similar preclinical data in patient-derived xenograft models of FRα-expressing cancer support the use of STRO-002 and carboplatin combinations, further supporting the potential of such combination approached,105 although this ADC has yet to be evaluated in clinical combination studies. The gene discussed is FOLR1; the disease is cancer.